The contribution of Asian researchers to the field of rheumatology

25. Holman, r. C., Curns, A. T., Belay, e. D.,
Steiner, C. A. & Schonberger, L. B. Kawasaki
syndrome hospitalizations in the United States,
1997 and 2000. Pediatrics 112, 495–501
(2003).
26. Burns, J. C. et al. Seasonality and temporal
clustering of Kawasaki syndrome. Epidemiology
16, 220–225 (2005).
27. Onouchi, Y. et al. ITPKC functional polymorphism
associated with Kawasaki disease susceptibility
and formation of coronary artery aneurysms.
Nat. Genet. 40, 35–42 (2008).
28. Birmann, B. M. et al. Population differences in
immune marker profiles associated with human
T‑lymphotropic virus type I infection in Japan and
Jamaica. Int. J. Cancer 124, 614–621 (2009).
29. Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K.
& Uchino, H. Adult T‑cell leukemia: clinical and
hematologic features of 16 cases. Blood 50,
481–492 (1977).
30. Nishioka, K., Sumida, T. & Hasunuma, T. Human
T lymphotropic virus type I in arthropathy and
autoimmune disorders. Arthritis Rheum. 39,
1410–1418 (1996).
31. Yamano, Y. et al. Virus‑induced dysfunction of
CD4 + CD25 + T cells in patients with
HTLV‑I‑associated neuroimmunological disease.
J. Clin. Invest. 115, 1361–1368 (2005).
32. Nakajima, T. et al. Overgrowth of human synovial
cells driven by the human T cell leukemia virus
type I tax gene. J. Clin. Invest. 92, 186–193
(1993).
33. Iwakura, Y. et al. Induction of inflammatory
arthropathy resembling rheumatoid arthritis in
mice transgenic for HTLV‑I. Science 253,
1026–1028 (1991).
34. Takayanagi, H. Mechanistic insight into
osteoclast differentiation in osteoimmunology.
J. Mol. Med. 83, 170–179 (2005).
35. Sato, K. & Takayanagi, H. Osteoclasts,
rheumatoid arthritis, and osteoimmunology. Curr.
Opin. Rheumatol. 18, 419–426 (2006).
36. Asagiri, M. & Takayanagi, H. The molecular
understanding of osteoclast differentiation.
Bone 40, 251–264 (2007).
37. Kong, Y. Y. et al. Activated T cells regulate bone
loss and joint destruction in adjuvant arthritis
through osteoprotegerin ligand. Nature 402,
304–309 (1999).
38. Takayanagi, H. et al. T‑cell‑mediated regulation of
osteoclastogenesis by signaling crosstalk
between rANKL and IFN‑gamma. Nature 408,
600–605 (2000).
39. Hori, S., Nomura, T. & Sakaguchi, S. Control of
regulatory T cell development by the
transcription factor Foxp3. Science 299,
1057–1061 (2003).
40. Miyara, M. et al. Functional delineation and
differentiation dynamics of human CD4 + T cells
expressing the FoxP3 transcription factor.
Immunity 30, 899–911 (2009).
41. Yamano, Y. et al. Abnormally high levels of virus‑
infected IFN‑γ + CCr4 + CD4 + CD25 + T cells in a
retrovirus‑associated neuroinflammatory
disorder. PLoS One 4, e6517 (2009).
42. Amano. T. et al. Synoviolin/Hrd1, an e3 ubiquitin
ligase, as a novel pathogenic factor for
arthropathy. Genes Dev. 17, 2436–2449 (2003).
43. Schroder, M. & Kaufman, r. J. The mammalian
unfolded protein response. Annu. Rev. Biochem.
74, 739–789 (2005).
44. Yamasaki, S. et al. Cytoplasmic destruction of
p53 by the endoplasmic reticulum‑resident
ubiquitin ligase ‘Synoviolin’. EMBO J. 26,
113–122 (2007).
45. Toh, M. L. et al. Overexpression of synoviolin in
peripheral blood and synoviocytes from
rheumatoid arthritis patients and continued
elevation in nonresponders to infliximab
treatment. Arthritis Rheum. 54, 2109–2118
(2006).
46. Sato, K. et al. reshaping a human antibody to
inhibit the interleukin 6‑dependent tumor cell
growth. Cancer Res. 53, 851–856 (1993).
47. Nishimoto, N. et al. Study of active controlled
tocilizumab monotherapy for rheumatoid
arthritis patients with an inadequate response
to methotrexate (SATOrI): significant reduction
in disease activity and serum vascular
endothelial growth factor by IL‑6 receptor
inhibition therapy. Mod. Rheumatol. 19, 12–19
(2009).
48. Smolen, J. S. et al. effect of interleukin‑6
receptor inhibition with tocilizumab in patients
with rheumatoid arthritis (OPTION study):
a double‑blind, placebo‑controlled, randomised
trial. Lancet 371, 987–997 (2008).
49. Genovese, M. C. et al. Interleukin‑6 receptor
inhibition with tocilizumab reduces disease
activity in rheumatoid arthritis with inadequate
response to disease‑modifying antirheumatic
drugs: the tocilizumab in combination with
traditional disease‑modifying antirheumatic drug
therapy study. Arthritis Rheum. 58, 2968–2980
(2008).
50. emery, P. et al. IL‑6 receptor inhibition with
tocilizmab improves treatment outcomes in
patients with rheumatoid arthritis refractory to
anti‑tumor necrosis factor biological: results
from a 24‑week multicentre randomized placebo‑
controlled trial. Ann. Rheum. Dis. 67,
1516–1523 (2008).
51. raff, M. C. Social controls on cell survival and
cell death. Nature 356, 397–400 (1992).
reviews
52. Yonehara, S., Ishii, A. & Yonehara, M. A cell‑
killing monoclonal antibody (anti‑Fas) to a cell
surface antigen co‑downregulated with the
receptor of tumor necrosis factor. J. Exp. Med.
169, 1747–1756 (1989).
53. Nagata, S. Apoptosis by death factor. Cell 88,
355–365 (1997).
54. Nishioka, K., Hasunuma, T., Kato, T., Sumida, T.
& Kobata, T. Apoptosis in rheumatoid arthritis:
a novel pathway in the regulation of synovial
tissue. Arthritis Rheum. 41, 1–9 (1998).
55. Cantwell, M. J., Hua, T., Zvaifler, N. J. &
Kipps, T. J. Deficient Fas ligand expression by
synovial lymphocytes from patients with
rheumatoid arthritis. Arthritis Rheum. 40,
1644–1652 (1997).
56. Kobayashi, T. et al. Differential regulation of Fas‑
mediated apoptosis of rheumatoid synoviocytes
by tumor necrosis factor alpha and basic
fibroblast growth factor is associated with the
expression of apoptosis‑related molecules.
Arthritis Rheum. 43, 1106–1114 (2000).
57. Salmon, M. et al. Inhibition of T cell apoptosis in
the rheumatoid synovium. J. Clin. Invest. 99,
439–446 (1997).
58. Perlman, H. et al. rheumatoid arthritis synovial
macrophages express the Fas‑associated death
domain‑like interleukin‑1β‑converting enzyme‑
inhibitory protein and are refractory to Fas‑
mediated apoptosis. Arthritis Rheum. 44, 21–30
(2001).
59. Fujisawa, K. et al. Therapeutic effect of the anti‑
Fas antibody on arthritis in HTLV‑1 tax
transgenic mice. J. Clin. Invest. 98, 271–278
(1996).
60. Matsuno, H. et al. Antirheumatic effects of
humanized anti‑Fas monoclonal antibody in
human rheumatoid arthritis/SCID mouse
chimera. J. Rheumatol. 29, 1609–1614 (2002).
61. Appelboom, T. et al. Preliminary results of a
phase I clinical trial of intra‑articular
administration of ArG098, a novel anti‑Fas IgM
Mab, in rA [presentation number 421].
Presented at the ACr/ArHP Scientific Meeting,
Philadelphia, PA (18 October 2009).
Acknowledgments
This work was partially supported by a Grant‑in‑Aid for
Scientific research from the Japan Society for the
Promotion of Science, The Ministry of education,
Culture, Sports, Science and Technology, Japanese
Ministry of Health, Labor, and welfare, National
Institute of Biomedical Innovation, Uehara Memorial
Foundation, Nagao Takeshi Nanbyo Foundation,
Kanagawa Nanbyo Foundation, Mishima Kaiun
Memorial Foundation, Takeda Science Foundation,
and ITSUU Laboratory research Foundation.
NATuRE REVIEWS | rheumATologY VOLuME 6 | FEBRuARY 2010 | 111
© 20 10
Macmillan Publishers Limited. All rights reserved